Association of monoaminergic gene polymorphisms in chronic inflammatory pulmonary disease patients with successful smoking cessation.
Rs4680 G/A COMT polymorphism
SNP
Smoking cessation
Smoking cues
Tonic dopamine
rs2235186
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
01
09
2023
accepted:
14
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
Albeit smoking cessation has unequivocal health benefits, attempts to quit are not unanimous, even in patient populations at high risk for smoking-related diseases cessation. Allelic variations of enzymes involved in dopamine metabolism are being considered as candidates for nicotine addiction. We set out to assess whether rs4680 G/A and rs2235186 G/A polymorphisms of COMT and MAO-A, respectively are associated with the ability to quit smoking in chronic inflammatory pulmonary disease patients. Patients managed for chronic inflammatory pulmonary disease by the Department of Pulmonology (University of Debrecen, Hungary), with a current or past smoking habit were included in the current analysis. The study was designed in line with the STROBE statement for cross-sectional studies and was approved by the National Center for Public Health, Hungary. Genomic DNA was extracted from peripheral blood specimens. SNPs were genotyped using TaqMan SNP genotyping assays. rs4680 COMT polymorphism showed significant effect for successful smoking cessation in patients with pulmonary disease. Accordingly, A/A subjects had lower odds for successful smoking cessation (odds ratio 0.37; 95% confidence interval 0.20-0.69, p = 0.002 (additive model). On the other hand, patients homozygous for the minor allele (A) at rs2235186 of MAO-A showed a non-significant trend toward increased odds for successful smoking cessation. The presence of the minor allele for rs4680 COMT was shown to decrease the odds for successful smoking cessation, a finding that may be interpreted in view of the altered balance between tonic and phasic dopamine release.
Sections du résumé
BACKGROUND
BACKGROUND
Albeit smoking cessation has unequivocal health benefits, attempts to quit are not unanimous, even in patient populations at high risk for smoking-related diseases cessation. Allelic variations of enzymes involved in dopamine metabolism are being considered as candidates for nicotine addiction. We set out to assess whether rs4680 G/A and rs2235186 G/A polymorphisms of COMT and MAO-A, respectively are associated with the ability to quit smoking in chronic inflammatory pulmonary disease patients.
METHODS
METHODS
Patients managed for chronic inflammatory pulmonary disease by the Department of Pulmonology (University of Debrecen, Hungary), with a current or past smoking habit were included in the current analysis. The study was designed in line with the STROBE statement for cross-sectional studies and was approved by the National Center for Public Health, Hungary. Genomic DNA was extracted from peripheral blood specimens. SNPs were genotyped using TaqMan SNP genotyping assays.
RESULTS
RESULTS
rs4680 COMT polymorphism showed significant effect for successful smoking cessation in patients with pulmonary disease. Accordingly, A/A subjects had lower odds for successful smoking cessation (odds ratio 0.37; 95% confidence interval 0.20-0.69, p = 0.002 (additive model). On the other hand, patients homozygous for the minor allele (A) at rs2235186 of MAO-A showed a non-significant trend toward increased odds for successful smoking cessation.
CONCLUSIONS
CONCLUSIONS
The presence of the minor allele for rs4680 COMT was shown to decrease the odds for successful smoking cessation, a finding that may be interpreted in view of the altered balance between tonic and phasic dopamine release.
Identifiants
pubmed: 39187813
doi: 10.1186/s12890-024-03219-y
pii: 10.1186/s12890-024-03219-y
doi:
Substances chimiques
Catechol O-Methyltransferase
EC 2.1.1.6
Monoamine Oxidase
EC 1.4.3.4
COMT protein, human
EC 2.1.1.6
monoamine oxidase A, human
EC 1.4.3.4.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
411Informations de copyright
© 2024. The Author(s).
Références
Drope J, Hamill S, Chaloupka F et al. Updated. The tobacco atlas. New York: Vital strategies and tobacconomics. https://tobaccoatlas.org/ . 2022. Accessed 12/15, 2022.
Babb S, Malarcher A, Schauer G, Asman K, Jamal A. Quitting smoking among adults - United States, 2000–2015. MMWR Morb Mortal Wkly Rep. 2017;65(52):1457–64. https://doi.org/10.15585/mmwr.mm6552a1 .
doi: 10.15585/mmwr.mm6552a1
pubmed: 28056007
Jin Y, Chen D, Hu Y, et al. Association between monoamine oxidase gene polymorphisms and smoking behaviour in Chinese males. Int J Neuropsychopharmacol. 2006;9(5):557–64. https://doi.org/10.1017/S1461145705006218 .
doi: 10.1017/S1461145705006218
pubmed: 16207390
Maes HH, Sullivan PF, Bulik CM, et al. A twin study of genetic and environmental influences on tobacco initiation, regular tobacco use and nicotine dependence. Psychol Med. 2004;34(7):1251–61. https://doi.org/10.1017/S0033291704002405 .
doi: 10.1017/S0033291704002405
pubmed: 15697051
Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J. 2009;33(3):468–80. https://doi.org/10.1183/09031936.00056908 .
doi: 10.1183/09031936.00056908
pubmed: 19251795
Jones SK, Wolf BJ, Froeliger B, Wallace K, Carpenter MJ, Alberg AJ. A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation. Drug Alcohol Depend. 2022;239:109596. https://doi.org/10.1016/j.drugalcdep.2022.109596 .
doi: 10.1016/j.drugalcdep.2022.109596
pubmed: 35981468
pmcid: 10876157
Tanner J, Tyndale RF. Variation in CYP2A6 activity and personalized medicine. JPM. 2017;7(4). https://doi.org/10.3390/jpm7040018 .
Chenoweth M, O’Loughlin J, Sylvestre M, Tyndale R. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenet Genomics. 2013;23(4):232–5. https://doi.org/10.1097/FPC.0b013e32835f834d .
doi: 10.1097/FPC.0b013e32835f834d
pubmed: 23462429
pmcid: 3744214
Brody AL, Mandelkern MA, Olmstead RE, et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry. 2006;63(7):808–16. https://doi.org/10.1001/archpsyc.63.7.808 .
doi: 10.1001/archpsyc.63.7.808
pubmed: 16818870
pmcid: 2873693
Pontieri FE, Tanda G, Orzi F, Chiara GD. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382(6588):255–7. https://doi.org/10.1038/382255a0 .
doi: 10.1038/382255a0
pubmed: 8717040
Leuchter AF, McCracken JT, Hunter AM, Cook IA, Alpert JE. Monoamine oxidase A and catechol-O-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol. 2009;29(4):372–7. https://doi.org/10.1097/JCP.0b013e3181ac4aaf .
doi: 10.1097/JCP.0b013e3181ac4aaf
pubmed: 19593178
Buckholtz JW, Callicott JH, Kolachana B, et al. Genetic variation in MAOA modulates ventromedial prefrontal circuitry mediating individual differences in human personality. Mol Psychiatry. 2008;13(3):313–24. https://doi.org/10.1038/sj.mp.4002020 .
doi: 10.1038/sj.mp.4002020
pubmed: 17519928
Nedic G, Nikolac M, Borovecki F, Hajnsek S, Muck-Seler D, Pivac N. Association study of a functional catechol-o-methyltransferase polymorphism and smoking in healthy caucasian subjects. Neurosci Lett. 2010;473(3):216–9. https://doi.org/10.1016/j.neulet.2010.02.050 .
doi: 10.1016/j.neulet.2010.02.050
pubmed: 20188797
Tiwari AK, Zai CC, Sajeev G, Arenovich T, Müller DJ, Kennedy JL. Analysis of 34 candidate genes in bupropion and placebo remission. Int J Neuropsychopharmacol. 2013;16(4):771–81. https://doi.org/10.1017/S1461145712000843 .
doi: 10.1017/S1461145712000843
pubmed: 22947179
Hotamisligil GS, Breakefield XO. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet. 1991;49(2):383–92. PMID: 1678250.
pubmed: 1678250
pmcid: 1683299
Bilder RM, Volavka J, Lachman HM, Graces AA. The catechol-O-methyltransferase polymorphism: relations to the Tonic–phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology (New York, N.Y.). 2004;29(11):1943–61. https://doi.org/10.1038/sj.npp.1300542
Lachman HM, Morrow B, Shprintzen R, et al. Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am J Med Genet. 1996;67(5):468. https://doi.org/10.1002/(SICI)1096-8628(19960920)67:5%3C;468::AID-AJMG5%3E;3.0.CO;2-G .
doi: 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G
pubmed: 8886163
Jansson M, McCarthy S, Sullivan PF, et al. MAOA haplotypes associated with thrombocyte-MAO activity. BMC Genet. 2005;6(1):46. https://doi.org/10.1186/1471-2156-6-46 .
doi: 10.1186/1471-2156-6-46
pubmed: 16174289
pmcid: 1249565
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of Observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–7. https://doi.org/10.1016/S0140-6736(07)61602-X .
doi: 10.1016/S0140-6736(07)61602-X
Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65. https://doi.org/10.1164/rccm.201204-0596PP .
doi: 10.1164/rccm.201204-0596PP
pubmed: 22878278
Boulet L, Fitzgerald JM, Levy ML, et al. A guide to the translation of the global initiative for asthma (GINA) strategy into improved care. Eur Respir J. 2012;39(5):1220–9.
doi: 10.1183/09031936.00184511
pubmed: 22282546
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom K. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Addiction (Abingdon England). 1991;86(9):1119–27. https://doi.org/10.1111/j.1360-0443.1991.tb01879.x .
doi: 10.1111/j.1360-0443.1991.tb01879.x
Zielińska-Danch W, Wardas W, Sobczak A, Szołtysek-Bołdys I. Estimation of urinary cotinine cut-off points distinguishing non-smokers, passive and active smokers. Biomarkers. 2007;12(5):484–96. https://doi.org/10.1080/13547500701421341 .
doi: 10.1080/13547500701421341
pubmed: 17701747
Mayo O. A century of hardy-Weinberg equilibrium. Twin Res Hum Genet. 2008;11(3):249–56. https://doi.org/10.1375/twin.11.3.249 .
doi: 10.1375/twin.11.3.249
pubmed: 18498203
Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol. 1999;39(1):19–52. https://doi.org/10.1146/annurev.pharmtox.39.1.19 .
doi: 10.1146/annurev.pharmtox.39.1.19
pubmed: 10331075
Colilla S, Lerman C, Shields P, et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet Genomics. 2005;15(6):393–8. https://doi.org/10.1097/01213011-200506000-00004 .
doi: 10.1097/01213011-200506000-00004
pubmed: 15900212
pmcid: 1262648
Omidvar M, Stolk L, Uitterlinden A, Hofman B, Duijn C, Tiemeier H. The effect of catechol-O-methyltransferase met/val functional polymorphism on smoking cessation: retrospective and prospective analyses in a cohort study. Pharmacogenet Genomics. 2009;19(1):45–51. https://doi.org/10.1097/FPC.0b013e328317f3f8 .
doi: 10.1097/FPC.0b013e328317f3f8
pubmed: 19160592
França R, Dautzenberg L, Falissard B, Reynaud M. Are social norms associated with smoking in French university students? A survey report on smoking correlates. Subst Abuse Treat Prev Policy. 2009;4(1):1–14. https://doi.org/10.1186/1747-597X-4-4 .
doi: 10.1186/1747-597X-4-4
Perkins JM, Perkins HW, Jurinsky J, Craig DW. Adolescent tobacco use and misperceptions of social norms across schools in the United States. J Stud Alcohol Drug. 2019;80(6):659–68. https://doi.org/10.15288/jsad.2019.80.659 .
doi: 10.15288/jsad.2019.80.659
Ton TGN, Rossing MA, Bowen DJ, Srinouanprachan S, Wicklund K, Farin FM. Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study. Behav Brain Funct. 2007;3(1):22. https://doi.org/10.1186/1744-9081-3-22 .
doi: 10.1186/1744-9081-3-22
pubmed: 17466074
pmcid: 1865548
Han D, Joe K, Na C, Lee Y. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in Korean male smokers. Psychiatr Genet. 2008;18(1):11–6. https://doi.org/10.1097/YPG.0b013e3282df0939 .
doi: 10.1097/YPG.0b013e3282df0939
pubmed: 18197080
Jones T, Smoking. cessation. Practice nursing. 2000;11(4):24–29. https://doi.org/10.12968/pnur.2000.11.4.9886
David SP, Johnstone E, Griffiths S, et al. No association between functional catechol O-methyl transferase 1947A > G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics (London). 2002;12(3):265–8. https://doi.org/10.1097/00008571-200204000-00011 .
doi: 10.1097/00008571-200204000-00011
Goto Y, Otani S, Grace AA. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology. 2007;53(5):583–7. https://doi.org/10.1016/j.neuropharm.2007.07.007 .
doi: 10.1016/j.neuropharm.2007.07.007
pubmed: 17709119
pmcid: 2078202
Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction (Abingdon England). 2000;95(8s2):119–28. https://doi.org/10.1046/j.1360-0443.95.8s2.1.x .
doi: 10.1046/j.1360-0443.95.8s2.1.x
Ou W, Huang Y, Huang C, et al. Interaction between cytochrome P450 2A6 and catechol-O-methyltransferase genes and their association with smoking risk in young men. Behav Brain Funct. 2017;13(1):8. https://doi.org/10.1186/s12993-017-0127-2 .
doi: 10.1186/s12993-017-0127-2
pubmed: 28472995
pmcid: 5418756
Johnstone EC, Elliot KM, David SP, Murphy MFG, Walton RT, Munafò MR. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1065–9. https://doi.org/10.1158/1055-9965.EPI-06-0936 .
doi: 10.1158/1055-9965.EPI-06-0936
pubmed: 17548664
pmcid: 2031911
Huotari M, Gogos JA, Karayiorgou M, et al. Brain catecholamine metabolism in catechol-O-methyltransferase (COMT)-deficient mice. Eur J Neurosci. 2002;15(2):246–56. https://doi.org/10.1046/j.0953-816x.2001.01856.x .
doi: 10.1046/j.0953-816x.2001.01856.x
pubmed: 11849292
Khanthiyong B, Thanoi S, Reynolds GP, Nudmamud-Thanoi S. Association study of the functional catechol-O-methyltranferase (COMT) Val158Met polymorphism on executive cognitive function in a Thai sample. Int J Med Sci. 2019;16(11):1461. https://doi.org/10.7150/ijms.35789 .
doi: 10.7150/ijms.35789
pubmed: 31673237
pmcid: 6818203
Wu J, Boström P, Sparks LM, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. Cell. 2012;150(2):366–76. https://doi.org/10.1016/j.cell.2012.05.016 .
doi: 10.1016/j.cell.2012.05.016
pubmed: 22796012
pmcid: 3402601
Knight HC, Smith DT, Ellison A. The role of the left dorsolateral prefrontal cortex in attentional bias. Neuropsychologia. 2020;148:107631. https://doi.org/10.1016/j.neuropsychologia.2020.107631 .
doi: 10.1016/j.neuropsychologia.2020.107631
pubmed: 32976854
Morris KA, Grace SA, Woods W, Dean B, Rossell SL. The influence of COMT rs4680 on functional connectivity in healthy adults: a systematic review. Eur J Neurosci. 2020;52(8):3851. https://doi.org/10.1111/ejn.14748 .
doi: 10.1111/ejn.14748
pubmed: 32306439
Nogueira NGHM, Bacelar MFB, Ferreira BP, Parma JO, Lage GM. Association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and motor behavior in healthy adults: a study review. Brain Res Bull. 2019;144:223–32. https://doi.org/10.1016/j.brainresbull.2018.11.002 .
doi: 10.1016/j.brainresbull.2018.11.002
pubmed: 30445182
Caporaso N, Gu F, Chatterjee N, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS ONE. 2009;4(2):e4653. https://doi.org/10.1371/journal.pone.0004653 .
doi: 10.1371/journal.pone.0004653
pubmed: 19247474
pmcid: 2644817
Eisenberger NI, Way BM, Taylor SE, Welch WT, Lieberman MD. Understanding genetic risk for aggression: Clues from the brain’s response to social exclusion. Biological psychiatry (1969). 2007;61(9):1100–1108. https://doi.org/10.1016/j.biopsych.2006.08.007
Tonnesen P. Smoking cessation and COPD. Eur Respiratory Rev. 2013;22(127):37–43. https://doi.org/10.1183/09059180.00007212 .
doi: 10.1183/09059180.00007212
Zhou X, Nonnemaker J, Sherrill B, Gilsenan AW, Coste F, West R. Attempts to quit smoking and relapse: factors associated with success or failure from the ATTEMPT cohort study. Addict Behav. 2008;34(4):365–73. https://doi.org/10.1016/j.addbeh.2008.11.013 .
doi: 10.1016/j.addbeh.2008.11.013
pubmed: 19097706